The University of Maryland BioPark and proximity to key stakeholders were two of the top reasons KaloCyte decided to move to Baltimore, its CEO said.

The company that is developing an artificial red blood cell moved to Baltimore from St. Louis last month.

“While we benefited greatly from our roots at St. Louis … as we started looking at comparing point-by-point the resources and the opportunities available with the move, it very quickly became a very easy business case to move,” said Elaine E. Haynes, KaloCyte’s CEO. “Staying behind would have just exacerbated our challenges.”

The embrace of Maryland’s startup and biotech communities has been a pleasant development for KaloCyte, but Haynes said that three factors were the main reasons KaloCyte moved to Baltimore. 

Read the full story from The Daily Record.